Why the AVITA (ASX:AVH) share price is charging higher today

The AVITA Medical Inc (ASX:AVH) share price is on the move on Friday following the release of its third quarter update…

| More on:
ASX shares profit upgrade chart showing growth

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The AVITA Medical Inc (ASX: AVH) share price is on the move on Friday morning.

At the time of writing, the regenerative medicine company's shares are up 4% to $5.35.

Why is the AVITA share price charging higher?

Investors have been buying the company's shares this morning following the release of its third quarter update.

According to the release, demand for the company's Recell system rebounded strongly during the quarter.

This led to AVITA recording revenue of US$8.8 million for the three months ended 31 March, which was a 126% increase over the prior corresponding period. Positively, this was also a 72.5% increase on its second quarter revenue.

Supporting this growth was an increase in procedural volumes. For the quarter, volumes reached 492. This compares to 408 in the prior corresponding period and 487 in the second quarter.

AVITA also advised that it added 6 new burn centre accounts during the three months, lifting its total to 99. This represents a penetration rate of 73% of the 136 total U.S. burn centres.

Furthermore, of the approximate 300 total U.S. burn surgeons, 244 have now been trained and certified with Recell. And 147 of these surgeons used Recell during the quarter.

Margins

AVITA's gross margin has softened over the last 12 months from 84% to 76%. This reflects a lower Recell price point for units that were purchased under contract with BARDA. The company's contract with BARDA was negotiated prior to the establishment of a higher price point achieved in the Recell commercialisation in the United States.

Positively, the company offset this with a reduction in its operating expenses. They came in at US$13.2 million for the third quarter, which is down from US$19.7 million a year earlier. Management advised that this was primarily attributable to lower stock-based compensation along with lower sales and marketing expenses.

Nevertheless, this wasn't enough to stop AVITA from recording a quarterly net loss of US$6 million. Though, this is a big improvement on last year's third quarter loss of US$15 million.

This left the company with cash of US$114.9 million at the end of the period.

Q4 guidance

Management advised that total revenue is expected to be in the range of US$8.2 million to US$8.6 million in the fourth quarter.

This comprises US$5 million to US$5.3 million of commercial Recell revenue and US$3.2 million to US$3.3 million of Recell revenue associated with BARDA.

AVITA's Chief Executive Officer, Dr. Mike Perry, said: "We made steady progress over the last quarter as we continued to drive RECELL usage in our established hospital burn center base with an increasing focus on smaller burns, and we continued to expand our physician training and outreach programs. As pandemic headwinds abate, we plan to leverage our highly experienced burns sales force and strong relationships built to date with the burn practitioner community to increase hospital access and to penetrate deeper into our existing accounts, resulting in additional procedures and engaging more burn practitioners."

"Our three pivotal clinical trials in vitiligo, trauma, and pediatric burns are continuing on schedule and we expect to see expanded indications for RECELL coming online, allowing us to serve an ever-growing population of patients," he added.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »